News & Events
Probiodrug to present at Alzheimer's and Parkinson's Diseases Congress
Published: 28 March 2017

Probiodrug to present at Alzheimer's and Parkinson's Diseases Congress

 New results of a double pronged-approach to target the neurotoxic amyloid beta species pGlu-Abeta, and an evaluation of new biomarkers in cerebrospinal fluid (CSF) from AD patients

HALLE (SAALE), Germany, 28 March 2017 - Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer's disease (AD), announced today that three updates on the advancement of its product candidates and the results of a Biomarker research collaboration will be presented at the 13th International Conference on Alzheimer's and Parkinson's Diseases (AD/PDTM 2017). The conference will take place in Vienna, Austria from 29th March to 2nd April 2017.

Dr. Inge Lues, Chief Development Officer of Probiodrug commented: "We are excited about the progress that has been made over the course of last year and the value added to our programs, and look forward to presenting the updates at the conference."

Program Presentations and Timing
QC- enzyme/CSF Biomarker
VUmed Center Amsterdam, The Netherlands
  • Cerebrospinal fluid glutaminyl cyclase (QC) activity correlates with Alzheimer's disease biomarkers and inflammation molecules in AD patients
  • Poster - 29th March - In CSF from AD patients high correlation of QC activity with AD related biomarkers and inflammatory molecules were found
QC-Inhibitor PQ912
Fraunhofer Institute,  Halle (Saale), Germany
  • Glutaminyl cyclase inhibition by PQ912 in transgenic mice with Alzheimer-like pathology-translation to clinics
  • Poster - 31st March - Based on  PKPD analysis in animal studies, a 50% inhibition of QC activity in the brain leads to a robust effect - an important translational guidance for therapeutic dosing in clinical studies
Anti-pGlu-Abeta MAB/QC-I
Harvard, BWH, Boston, USA
  • Murine anti-pyroglutamate-3 Abeta MAB, 07/2a, spares cognition, reduces plaques, and, in combination with glutaminyl cyclase inhibitor PQ912 further improves efficacy
  • Oral Presentation - 29th March / 11:45-12:00 -Selective targeting of pGlu-Abeta with an IgG2a in tg mice is effective in lowering plaque pathology and improving cognition a combination of a  QC-inhibitor and a pGlu-Abeta specific antibody showed superior efficacy


For more information, please contact:

Dr Konrad Glund, CEO

Hume Brophy
Conor Griffin, Alexia Faure, Alexander Protsenko
Tel: +44 (0) 20 7862 6381

The Trout Group
Tricia Truehart
Tel: +1 (646) 378-2953

MC Services AG
Anne Hennecke, Caroline Bergmann
Tel: +49 (0) 211 529 252 20

Notes to Editors:
About Probiodrug AG
Headquartered in Halle (Saale), Germany, Probiodrug AG (Euronext Amsterdam: PBD) is a biopharmaceutical company focused on the development of new therapeutic products for the treatment of Alzheimer's disease.

Founded in 1997, the company successfully developed a novel therapeutic concept for diabetes - the DP4 inhibitors - which provided the basis for a novel class of antidiabetics - the gliptins. Its core capabilities are based on its long-standing expertise in the elucidation of the structure and function of enzymes involved in the modification of proteins and peptides, which play a central role in pathological conditions.

Today Probiodrug's aim is to become a leading company in the development of Alzheimer's disease treatments and to thereby provide a better life for Alzheimer's disease patients. It has identified a new therapeutic concept linked to disease initiation and progression. The development approaches are targeting pyroglutamate-Abeta (pGlu-Abeta) as a therapeutic strategy to fight Alzheimer's disease. The Company has medical use and composition of matter patents related to the inhibition of Glutaminyl Cyclase (QC) and anti-pGlu-Abeta- specific monoclonal antibodies, providing it, in the Company's view, with a leading position in this field of research.

Probiodrug's lead product candidate, PQ912, is a highly specific and potent inhibitor of Glutaminyl Cyclase (QC), which has shown therapeutic effects in Alzheimer's animal models. PQ912 is currently in a Phase 2a study, the SAPHIR trial. In a preceding Phase 1 study with healthy young and elderly volunteers, PQ912 has shown to be safe and well tolerated and also revealed high QC-inhibition.

About Alzheimer's disease
Alzheimer's disease is a neurological disorder, which is the most common form of dementia, and ultimately leads to death. Because Alzheimer's disease cannot be cured and is degenerative, the affected patients must increasingly rely on others for assistance. Today, 47 million people live with dementia worldwide, and this number is projected to treble to more than 131 million by 2050, as populations age. Dementia also has a huge economic impact. Alzheimer's has an estimated, global societal cost of US$ 818 billion, and it will become a trillion dollar disease by 2018. (World Alzheimer Report 2016).

Forward Looking Statements
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgment of Probiodrug AG as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.